The Accelerated Approval Program for Cancer Drugs — Finding the Right Balance

Abstract

Recently, the FDA proposed guidance that would update the accelerated approval pathway for cancer drugs. Although the guidance includes important provisions, it could be strengthened.

Cite this work

No public copy is stored for this record, so only the metadata is cited.

Stored only when both papers are in the corpus — 46 citations exist upstream.

Papers that cite the same references — the relational fallback while embeddings are still backfilling.